Clinical Omissions in COVID-19

M J Quinn¹

Affiliations

Comment

M J Quinn. Am J Med. 2021 Aug.

. 2021 Aug;134(8):e463.

doi: 10.1016/j.amjmed.2021.01.036.

M J Quinn¹

No abstract available

Comment in

The Reply.
McCullough PA. McCullough PA. Am J Med. 2021 Aug;134(8):e464. doi: 10.1016/j.amjmed.2021.02.023. Am J Med. 2021. PMID: 34340752 Free PMC article. No abstract available.

Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection.
McCullough PA, Kelly RJ, Ruocco G, Lerma E, Tumlin J, Wheelan KR, Katz N, Lepor NE, Vijay K, Carter H, Singh B, McCullough SP, Bhambi BK, Palazzuoli A, De Ferrari GM, Milligan GP, Safder T, Tecson KM, Wang DD, McKinnon JE, O'Neill WW, Zervos M, Risch HA. McCullough PA, et al. Am J Med. 2021 Jan;134(1):16-22. doi: 10.1016/j.amjmed.2020.07.003. Epub 2020 Aug 7. Am J Med. 2021. PMID: 32771461 Free PMC article. Review.

1. McCullough PA, Kelly RJ, Ruocco G, et al. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med. 2021;134(1):16–22. - PMC - PubMed
1. Han H, Ma Q, Li C, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9:1123–1130. - PMC - PubMed
1. Bösmüller H, Traxler S, Bitzer M, et al. The evolution of pulmonary pathology in fatal COVID-19 disease: an autopsy study with clinical correlation. Virchows Arch. 2020;477:349–357. - PMC - PubMed
1. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. - PMC - PubMed
1. Fareed GC, Jacobs MM, Pompan DC. The Desert Review. Open letter to Dr. Anthony Fauci regarding the use of hydroxychloroquine for treating COVID-19. Available at:https://www.thedesertreview.com/opinion/columnists/open-letter-to-dr-ant.... Accessed January 19, 2021.